Marion Dorsch - Blueprint Medicines Chief Scientific Officer
| BPMC Stock | USD 92.26 0.03 0.03% |
Executive
Dr. Marion Dorsch, Ph.D., was appointed as Chief Scientific Officer of the Company. Dr. Dorsch has served as our chief scientific officer since November 2016. Prior to joining us, from April 2012 to November 2016, Dr. Dorsch served as Vice President of Biology at Agios Pharmaceuticals, Inc., or Agios. In this role, she was responsible for novel target validation, drug discovery, and biomarker strategy across Agios cancer, rare genetic diseases and immunooncology portfolios. During her tenure at Agios, Dr. Dorsch contributed to the successful advancement of several molecules targeting defined genetic lesions into clinical trials. Prior to joining Agios, Dr. Dorsch was the Director of Cancer Biology at Sanofi Oncology, where she oversaw drug discovery efforts. Earlier in her career, Dr. Dorsch served as research project leader for sonidegib, now approved in the United States and European Union for the treatment of locally advanced basal cell carcinoma, at the Novartis Institutes for Biomedical Research and also worked in Inflammation Discovery at Millennium Pharmaceuticals, Inc since 2016.
| Age | 53 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Address | 45 Sidney Street, Cambridge, MA, United States, 02139 |
| Phone | 617 374 7580 |
| Web | https://www.blueprintmedicines.com |
Blueprint Medicines Management Efficiency
The company has return on total asset (ROA) of (0.2534) % which means that it has lost $0.2534 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5714) %, meaning that it created substantial loss on money invested by shareholders. Blueprint Medicines' management efficiency ratios could be used to measure how well Blueprint Medicines manages its routine affairs as well as how well it operates its assets and liabilities. As of April 25, 2024, Return On Tangible Assets is expected to decline to -0.51. In addition to that, Return On Capital Employed is expected to decline to -0.61. At present, Blueprint Medicines' Other Current Assets are projected to decrease significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 613.2 M, whereas Total Assets are forecasted to decline to about 784.9 M.Similar Executives
| Found 12 records | EXECUTIVE Age | ||
| Philippa Keith | Terns Pharmaceuticals | N/A | |
| Emil MD | Terns Pharmaceuticals | 43 | |
| Tammy Sarnelli | Amylyx Pharmaceuticals | N/A | |
| Gayle Gironda | Inozyme PharmaInc | N/A | |
| Soojin Kim | Inozyme PharmaInc | N/A | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
| Lindsey Allen | Amylyx Pharmaceuticals | N/A | |
| Robyn MA | Acumen Pharmaceuticals | N/A | |
| JD Esq | Acumen Pharmaceuticals | 53 | |
| Jeffrey Jasper | Terns Pharmaceuticals | N/A | |
| Keith White | Amylyx Pharmaceuticals | N/A | |
| Linda Arsenault | Amylyx Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -1.57 | ||||
| Return On Asset | -0.25 |
Blueprint Medicines Corp Leadership Team
Elected by the shareholders, the Blueprint Medicines' board of directors comprises two types of representatives: Blueprint Medicines inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Blueprint. The board's role is to monitor Blueprint Medicines' management team and ensure that shareholders' interests are well served. Blueprint Medicines' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Blueprint Medicines' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nicholas Lydon, Director | ||
| Michael Landsittel, Interim Principal Accounting and Financial Officer and Sr. Director of Fin. | ||
| George Demetri, Independent Director | ||
| Dr MBA, Chief Officer | ||
| Anthony Boral, Senior Vice President - Clinical Development | ||
| Tracey Esq, Chief VP | ||
| Kathryn Haviland, Chief Business Officer | ||
| Jeffrey Albers, President CEO, Director | ||
| Alexis Borisy, Director | ||
| Stephen Knight, Director | ||
| Christopher Murray, Senior Vice President Technical Operations | ||
| Tracey McCain, Executive Vice President Chief Legal Officer, Secretary | ||
| Alexis AM, CoFounder Director | ||
| Daniel Lynch, Chairman of the Board | ||
| Marion Dorsch, Chief Scientific Officer | ||
| Mark Goldberg, Director | ||
| Fouad MD, President Development | ||
| Kristin Hodous, IR Contact Officer | ||
| Charles Rowland, Independent Director | ||
| Ariel Hurley, Principal Accounting Officer | ||
| Christina Rossi, Chief Commercial Officer | ||
| Lonnel Coats, Independent Director | ||
| JD MBA, Ex Chairman | ||
| Jenna Cohen, Director Relations | ||
| Christoph Lengauer, Chief Scientific Officer | ||
| Thilo Schroeder, Director | ||
| Lynn Seely, Director |
Blueprint Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Blueprint Medicines a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.57 | ||||
| Return On Asset | -0.25 | ||||
| Profit Margin | (2.03) % | ||||
| Operating Margin | (1.46) % | ||||
| Current Valuation | 5.71 B | ||||
| Shares Outstanding | 61.23 M | ||||
| Shares Owned By Insiders | 0.85 % | ||||
| Shares Owned By Institutions | 99.15 % | ||||
| Number Of Shares Shorted | 4.37 M | ||||
| Price To Earning | 7.93 X |
Blueprint Medicines Investors Sentiment
The influence of Blueprint Medicines' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Blueprint. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Blueprint Medicines' public news can be used to forecast risks associated with an investment in Blueprint. The trend in average sentiment can be used to explain how an investor holding Blueprint can time the market purely based on public headlines and social activities around Blueprint Medicines Corp. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Blueprint Medicines' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Blueprint Medicines' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Blueprint Medicines' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Blueprint Medicines.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Blueprint Medicines in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Blueprint Medicines' short interest history, or implied volatility extrapolated from Blueprint Medicines options trading.
Pair Trading with Blueprint Medicines
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Blueprint Medicines position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will appreciate offsetting losses from the drop in the long position's value.Moving together with Blueprint Stock
| 0.78 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
| 0.66 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
Moving against Blueprint Stock
| 0.43 | GILD | Gilead Sciences Earnings Call Today | PairCorr |
The ability to find closely correlated positions to Blueprint Medicines could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Blueprint Medicines when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Blueprint Medicines - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Blueprint Medicines Corp to buy it.
The correlation of Blueprint Medicines is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Blueprint Medicines moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Blueprint Medicines Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Blueprint Medicines can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
Is Blueprint Medicines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.37) | Revenue Per Share 4.118 | Quarterly Revenue Growth 0.855 | Return On Assets (0.25) | Return On Equity (1.57) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.